Tislelizumab: First Approval

2020/03/18 by Arnold Lee, Susan J. Keam · 26 citations
Medicine · Immunology and Microbiology · #Cancer Immunotherapy and Biomarkers #CAR-T cell therapy research #Immunotherapy and Immune Responses

paper · doi:10.1007/s40265-020-01286-z

Cited by

• Structure and function of therapeutic antibodies approved by the US FDA in 2024
• Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody. [europepmc]
• Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. [europepmc]
• Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. [europepmc]
• Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient. [europepmc]
• Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. [europepmc]
• Experience with regorafenib in the treatment of hepatocellular carcinoma. [europepmc]
• Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy. [europepmc]
• Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China. [europepmc]
• Generation, secretion and degradation of cancer immunotherapy target PD-L1. [europepmc]
• Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). [europepmc]
• Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews. [europepmc]
• Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. [europepmc]
• HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. [europepmc]
• Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study. [europepmc]
• Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study. [europepmc]
• A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. [europepmc]
• Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging. [europepmc]
• Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1. [europepmc]
• Hot and cold tumors: Immunological features and the therapeutic strategies. [europepmc]
• Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody. [europepmc]
• Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy. [europepmc]
• Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial. [europepmc]
• Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors. [europepmc]
• Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies. [europepmc]
• Current landscape of innovative drug development and regulatory support in China. [europepmc]